Xurocitam Max Tablet contains Betahistine 16 mg, Piracetam 800 mg, and Vinpocetine 5 mg, a triple-action neuro-vascular formulation designed to support vertigo control, balance improvement, and cerebral blood flow enhancement.
Betahistine improves inner ear microcirculation and vestibular function, helping reduce vertigo attacks, dizziness, and nausea. Piracetam supports neuronal metabolism and neurotransmission, improving cognitive stability associated with vestibular disorders, while Vinpocetine enhances cerebral circulation and oxygen utilization, supporting overall brain performance.
Clinically, this combination is widely used in Ménière’s disease, vestibular dysfunction, chronic dizziness, cerebral insufficiency, and neuro-circulatory weakness. The tablet formulation ensures precise dosing, consistent efficacy, and strong patient compliance.
Xurocitam Max Tablet strengthens the vertigo and neuro care therapy segment, with regular use in ENT clinics, neurology practice, and general medicine, offering reliable symptom relief, long-term management benefits, and strong prescriber confidence.